One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

Experts predict that physicians may favour emerging biosimilar versions of Stelara over more effective originator IL-23 drugs ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

“There are prescription salicylic acid shampoos that can be used to treat psoriasis or dandruff ... look for depends a lot on ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Treatment varies from person to person but typically involves a prescription medication or topical cream. Avoiding things ...

Arcutis Biotherapeutics (ARQT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday.

A nasal swab might one day be able to predict the severity of a COVID infection In a new study, higher levels of ...